Combating Antibiotic Resistance with PCT-aided Decision Making
Recorded On: 04/26/2023
This Thermo Fisher sponsored session was part of the Sepsis Alliance AMR Conference 2023.
B·R·A·H·M·S PCT is an invaluable marker to help assess presence or absence of a bacterial infection and can be used as an aid in antibiotic therapy for patients with suspected or confirmed lower respiratory tract infection (LRTI). This sponsored session reviews the utility of procalcitonin (PCT) testing to aid initiation and discontinuation of antibiotics for patients with clinical presentation of bacterial infection. Join Dr. Mike Broyles as he discusses the ways B·R·A·H·M·S PCT supports the responsible use of antibiotics to prolong their effectiveness.
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Sepsis Alliance gratefully acknowledges the support of this session provided by Thermo Fisher.
Michael Broyles, PharmD
Director of Medical Affairs, Biomarkers
Mike Broyles, PharmD has more than 30 years of experience as a Hospital Pharmacy and Laboratory Director providing patients with current concepts in the clinical use of drugs with a focus on antimicrobial stewardship. His current role is Director of Medical Affairs, Biomarkers for Thermo Fisher Scientific. Prior to joining Thermo Fisher Scientific, Mike had more than 25 years consulting for a large IHN as their pharmacy advisory chairman to develop and implement clinical initiatives. His goal is to provide the leading thought processes in patient management and use technology to enhance the ability of clinicians to have the best options in patient’s clinical status, decision support, and improving outcomes through better clinical care.